Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) filed a Current Report on Form 8-K dated December 23, 2025. The company is a Delaware corporation headquartered in San Diego, California, with common stock trading on The Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes and Corporate Actions
- Amendment to Sale Agreement: On December 23, 2025, the Company entered into Amendment No. 1 to its Open Market Sale Agreement with Jefferies LLC. This amendment authorizes the issuance of an additional $459,972,480 of common stock under an "at the market" offering program. It also includes administrative changes regarding settlement and the auditor comfort process.
- Authorized Share Increase: The Company previously approved an amendment to its Amended and Restated Certificate of Incorporation to increase authorized common stock from 1,350,000,000 shares to 1,650,000,000 shares. This amendment became effective on November 10, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond standard legal disclaimers regarding the validity of the securities offering. The Company noted that the sale of shares is subject to registration and qualification under applicable securities laws.
Investor Verification Checklist
- Verify the total remaining capacity under the amended "at the market" offering program.
- Review the full text of the Amendment No. 1 to the Open Market Sale Agreement (Exhibit 10.1) for specific terms regarding sales agent compensation and settlement procedures.
- Confirm the current number of outstanding shares to assess the dilution impact of the newly authorized share increase.
- Check subsequent filings for any actual sales of shares under the amended program.